The bill amends section 340E of the Public Health Service Act to extend the authorization for payments to children’s hospitals that run graduate medical education (GME) programs through fiscal year 2030, and to increase specified authorized funding levels for 2026–2030. It adds a new, categorical prohibition: a children’s hospital that furnished certain listed surgeries or provided specified drugs to patients under 18 during a prior measurement period becomes ineligible for program payments for the following fiscal year, with a narrow transition rule for FY2026.
This change ties federal GME support to hospitals’ pediatric care choices. The practical effect: hospitals that provide the enumerated gender‑affirming procedures or prescribe hormones/puberty blockers to minors risk losing a stream of federal GME dollars; the bill also preserves narrow clinical exceptions (precocious puberty, differences/disorders of sex development, complications of prior care, and imminent life‑threatening conditions) and excludes non‑procedural mental or behavioral health treatment for gender dysphoria from the penalty.
Compliance tracking, payment administration, and training program impacts follow directly from the new eligibility condition.
At a Glance
What It Does
Extends the GME payments program for children’s hospitals through FY2030, raises the program’s authorized funding levels for fiscal years 2026–2030, and prohibits payments to any children’s hospital that, during the preceding measurement period, furnished a specified list of surgeries or provided certain hormone and puberty‑blocking drugs to individuals under 18. The bill defines the covered procedures and drugs and lists clinical exceptions.
Who It Affects
Children’s hospitals that operate graduate medical education programs; pediatric residency and fellowship trainees at those hospitals; hospitals’ billing, compliance, and medical staff who must track pediatric services; and pediatric patients who receive (or seek) the listed procedures or drugs. HRSA (the administering agency) will administer the eligibility condition.
Why It Matters
It makes federal GME dollars contingent on hospital clinical decisions about gender‑related care for minors, creating direct financial incentives that will influence hospital service lines, training opportunities in pediatric gender care, and operational compliance obligations. The definition of covered drugs and the listed surgeries also creates new reporting and enforcement questions for administrators and clinicians.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill modifies the existing children’s hospital GME payments program (section 340E of the Public Health Service Act). First, it extends the statutory authorization window from its prior end date to the end of fiscal year 2030 and adds specific annual authorized funding amounts for fiscal years 2026–2030.
Those are the program’s spending authorizations; the bill does not change the basic GME payment formula but adjusts the statutory life and funding ceiling of the program.
Second, the core substantive change is an eligibility condition: starting with fiscal year 2026, a children’s hospital becomes ineligible for program payments if, at any point during the preceding fiscal year (with a defined short transition period for FY2026), it furnished any item on a defined list of surgeries or provided certain puberty‑blocking or sex‑hormone medications to patients under 18. The list of surgeries is extensive and specific (it names many procedures commonly described as gender‑affirming surgeries), and the drugs clause explicitly covers GnRH analogues (puberty blockers) and sex hormones when administered in amounts greater than normal endogenous production for the patient’s age and sex.Third, the bill builds in several narrow clinical exceptions and a carve‑out for non‑procedural behavioral health care: it permits payments to hospitals that treated minors for precocious puberty with parental consent, that provided medically necessary treatment for diagnosed differences/disorders of sex development (DSD) based on genetic or biochemical testing, that treated infections or injuries caused by prior procedures, or that performed procedures necessary to avoid imminent death or major bodily impairment.
The bill also specifies that furnishing mental or behavioral health services for gender dysphoria (so long as those services do not include the listed procedures or drugs) does not trigger the payment prohibition.Operationally, the statute changes who receives federal GME support by linking eligibility to clinical activity. Hospitals will need to track whether they furnished any covered procedure or drug to any patient under 18 during the relevant look‑back period and adjust their expectations for federal payments accordingly.
The agency managing the program will need to operationalize verification and enforcement of the new eligibility rule and apply the FY2026 transition timing when assessing initial compliance.
The Five Things You Need to Know
The bill extends the children’s hospital GME payments authorization under 42 U.S.C. 256e through fiscal year 2030 (previously authorized through 2023).
For fiscal years 2026–2030 the bill adds two specific authorization lines: $124,000,000 per year (new paragraph (1)(A)(vii)) and $261,000,000 per year (new paragraph (2)(G)).
Beginning with fiscal year 2026, the bill prohibits any payment to a children’s hospital if, during the preceding fiscal year, the hospital furnished one or more enumerated surgeries or provided specified puberty‑blocking or sex‑hormone drugs to patients under 18.
The statute lists detailed surgical procedures (e.g.
orchiectomy, vaginoplasty, phalloplasty, mastectomy, chondrolaryngoplasty, facial feminization/masculinization procedures, and certain implant placements) and covers GnRH analogues and sex hormones administered 'in an amount greater than would normally be produced endogenously' for the minor’s age and sex.
Narrow exceptions preserve payments where care was for precocious puberty (with parental consent), medically necessary treatment of differences/disorders of sex development confirmed by testing, treatment of infection or injury caused by prior procedures, or procedures required to prevent imminent death or major bodily impairment; behavioral health treatment for gender dysphoria that does not include the listed procedures or drugs is also exempt.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Designates the act as the 'Children’s Hospital GME Support Reauthorization Act of 2025.' This is purely a captioning provision; it does not change substance or administration but identifies the statute for citation.
Extend program authorization to FY2030
Amends the authorization date in subsection (a) to move the program’s expiration to the end of fiscal year 2030. Practically, this keeps the statutory authority for payments intact and prevents an imminent lapse in the program’s authorization, subject to appropriations.
Adds specific annual authorized funding amounts for 2026–2030
Adds $124 million in one authorization clause and $261 million in another for each fiscal year 2026–2030. These are statutory authorizations of appropriations for program components; they do not themselves appropriate funds but set Congress’s authorization ceiling that appropriators typically reference when budgeting.
Payment prohibition tied to furnishing specified procedures or drugs to under‑18 patients
Inserts a new paragraph that makes a hospital ineligible for payments for any fiscal year (beginning with FY2026) if it furnished specified procedures or drugs to individuals under 18 during the preceding fiscal year. The provision includes a special transitional rule for FY2026: eligibility for any payment portion of FY2026 applies only to conduct after Dec 31, 2025, and the 'preceding fiscal year' for that initial determination is defined as Sept 1–Dec 31, 2025. The section also clarifies that furnishing only mental or behavioral health services for gender dysphoria that do not include the listed procedures/drugs does not trigger the prohibition.
Defines 'specified procedures and drugs' and creates clinical exceptions
Adds a detailed enumeration of covered surgeries and specifies covered drugs (e.g., GnRH analogues and sex hormones given at supra‑endogenous doses). It then carves out exceptions: (1) puberty suppression for diagnosed precocious puberty with parental consent; (2) medically necessary treatments for diagnosed differences/disorders of sex development confirmed by testing; (3) treatment of infection/injury/disease caused or worsened by prior procedures listed; and (4) procedures required to avert imminent death or major bodily impairment. The provision also defines 'sex' for purposes of the subsection in biological terms (chromosomes, hormones, gonads, genitalia). Practically, these text choices establish bright‑line lists but also create interpretation and documentation obligations for clinicians and administrators.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Children's hospitals that do not perform the listed procedures or prescribe the specified drugs to minors — they preserve eligibility for federal GME payments and avoid the financial penalty the statute imposes.
- Pediatric patients with clinically diagnosed precocious puberty or medically verifiable differences/disorders of sex development — the bill explicitly preserves access to puberty‑suppressing drugs for precocious puberty and medically necessary treatment of DSD under the exceptions.
- Graduate medical education programs that are hosted by hospitals that comply with the new eligibility condition — those residency and fellowship slots retain federal GME funding, which supports program budgets and training capacity.
Who Bears the Cost
- Children's hospitals that provide the enumerated gender‑affirming surgeries or that prescribe puberty blockers or cross‑sex hormones to patients under 18 — they risk losing program payments and related budgetary support for GME.
- Pediatric patients under 18 seeking the listed procedures or hormone treatments at affected hospitals — the conditional funding may reduce local availability of those services or shift care to other settings.
- Hospital compliance, clinical, and administrative teams — hospitals must build or adapt tracking, documentation, and reporting processes to determine whether any covered care to minors was furnished during the measurement period and to demonstrate eligibility, increasing administrative workload and potential legal risk.
Key Issues
The Core Tension
The bill forces a trade‑off between using federal payment conditions to pursue a public‑policy objective (limiting certain gender‑affirming medical and surgical care for minors) and preserving clinical autonomy and access to care within pediatric hospitals; it resolves the policy question by attaching financial consequences to clinical conduct, but that mechanism inevitably pits program integrity and policy control against medical discretion, training needs, and potential unintended effects on non‑targeted pediatric care.
The statute creates several implementation and interpretation challenges that will determine its practical effect. First, enforcement is implicit: payments are barred when a hospital 'furnished' covered care during the look‑back period.
The bill does not add a detailed reporting mechanism, audit standard, or appeal process in the text; HRSA (the current program administrator) will need to specify how it will detect, verify, and resolve alleged ineligible activity. That raises questions about what documentation hospitals must keep, what thresholds trigger agency review, and how retroactive payment adjustments will be handled.
Second, the statutory definitions are specific but imperfectly tailored to clinical practice. The drugs clause hinges on dosage language—'in an amount greater than would normally be produced endogenously'—which introduces measurement ambiguity for clinicians who titrate hormones for individual patients.
The long list of named surgical procedures covers many but not all conceivable interventions; borderline procedures or reconstructive surgeries that have mixed indications may require case‑by‑case interpretation. Those ambiguities create a real risk of a precautionary response: hospitals could limit or withdraw entire service lines (including noncontroversial pediatric surgical or endocrine care) to avoid jeopardizing GME funding.
Finally, the exceptions narrow the statute’s reach in some clinical scenarios (precocious puberty, DSD, infection/complication management, imminent threat to life), but they leave open questions about documentation standards, the role of parental consent, and the interplay with state laws and insurance coverage. The FY2026 transition timing is unusual and may create asymmetric incentives in the initial months.
Together, these implementation gaps — enforcement protocol, definitional precision, and documentation standards — will determine whether the bill produces targeted compliance or broader chilling effects on pediatric clinical services and training.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.